Abstract

Objective: This study examined the efficacy and safety of adjunctive mixed d-amphetamine/l-amphetamine salt (MAS; Mydayis) in adults with DSM-IV-TR–confirmed bipolar I or II depression.

Methods: In this 8-week, randomized, placebo-controlled 2-site study of adjunctive MAS, the primary outcome was baseline-to-end point change in the Montgomery-Asberg Depression Rating Scale (MADRS). Secondary outcomes included, in part, treatment response and remission (≥50% MADRS reduction, MADRS <10) and illness improvement as measured by the Clinical Global Impression for Bipolar Disorder (CGI-BP). The primary safety assessment was the Young Mania Rating Scale (YMRS). The 8-week controlled trial was followed by an 8-week open-label extension.

Results: Thirty-two (14 with bipolar I disorder, 18 with bipolar II disorder; 10 male, 22 female; mean age=38.2 y) patients enrolled in the study. Baseline symptoms (MADRS = 27.0±6.3, Quick Inventory of Depressive Symptomatology–Clinician-Rated = 15.3±3.2, Quick Inventory of Depressive Symptomatology–Self-Report = 14.8±4.7, and YMRS = 4.0) were consistent with moderate depression and absence of hypomania. Baseline demographics showed no significant group differences. In age-adjusted analyses, participants receiving adjunctive MAS (n = 15) showed significantly greater improvement on MADRS compared to placebo (n = 17, mean percent reduction: 62.3% vs 15.4%; P= .002), with higher rates of remission (63.3% vs 8.5%; P= .002) and response (79.5% vs 7.3%; P <.001). CGI-BP ratings of “much improved” or “very much improved” were higher with MAS (67.0% vs 10.2%; P= .001). No significant differences were observed in YMRS (last observation 2.9 vs 3.3; P= .72). The open-label extension (n = 24) showed maintenance of response, with 1 participant experiencing a switch to mania and 2 participants with drug misuse.

Conclusions: Adjunctive MAS was associated with effective reduction in depression symptoms with broad safety profile for most participants. Secondary analyses are encouraged to examine differential response rates by mood stabilizer and item analyses of attention and eating behavior.

Trial Registration: ClinicalTrials.gov identifier: NCT04235686.

J Clin Psychiatry 2026;87(4):26m16446

Author affiliations are listed at the end of this article.

From the Editors

Members Only Content

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you're already a subscriber, please log in below to continue reading.

Subscribe Now

Already a member? Log in

  1. Fiedorowicz JG, Persons JE, Assari S, et al. Depressive symptoms carry an increased risk for suicidal ideation and behavior in bipolar disorder without any additional contribution of mixed symptoms. J Affect Disord. 2019; 246:775–782. PubMed CrossRef
  2. Singh B, Swartz HA, Cuellar-Barboza AB, et al. Bipolar disorder. Lancet. 2025; 406(10506):963–978. PubMed CrossRef
  3. Rhee TG, Olfson M, Nierenberg AA, et al. 20-Year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatr. 2020;2020:19091000.
  4. Singh B, Yocum AK, Strawbridge R, et al. Patterns of pharmacotherapy for bipolar disorder: a GBC survey. Bipolar Disord. 2024;26(1):22–32. PubMed CrossRef
  5. Grunze H, Born C. The impact of subsyndromal bipolar symptoms on patient’s functionality and quality of life. Front Psychiatry. 2020;11:510. PubMed CrossRef
  6. Samalin L, de Chazeron I, Vieta E, et al. Residual symptoms and specific functional impairments in euthymic patients with bipolar disorder. Bipolar Disord. 2016;18(2):164–173. PubMed CrossRef
  7. Altshuler LL, Post RM, Black DO, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry. 2006;67(10):1551–1560. PubMed CrossRef
  8. Nierenberg AA, Agustini B, Köhler-Forsberg O, et al. Diagnosis and treatment of bipolar disorder: a review. JAMA. 2023;330(14):1370–1380. PubMed CrossRef
  9. Judd LL, Schettler PJ, Akiskal HS, et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Archives Gen Psychiatry. 2008;65(4):386–394. PubMed CrossRef
  10. Adler LA, Frick G, Yan B. A long-term, open-label, safety study of triple-bead mixed amphetamine salts (SHP465) in adults with ADHD. J Atten Disord. 2020; 24(3):434–446. PubMed CrossRef
  11. Frick G, Yan B, Adler LA. Triple-Bead mixed amphetamine salts (SHP465) in adults with ADHD: results of a phase 3, double-blind, randomized, forced-dose trial. J Atten Disord. 2020;24(3):402–413. PubMed CrossRef
  12. Spencer TJ, Adler LA, Weisler RH, et al. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008; 69(9):1437–1448. PubMed CrossRef
  13. Uhl GR, Li S, Takahashi N, et al. The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB J. 2000;14(15):2459–2465. PubMed CrossRef
  14. Easton N, Steward C, Marshall F, et al. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology. 2007;52(2):405–414. PubMed CrossRef
  15. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology. 2009;57(7):608–618. PubMed CrossRef
  16. Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–270. PubMed CrossRef
  17. Sonders MS, Zhu S-J, Zahniser NR, et al. Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci. 1997;17(3):960–974. PubMed
  18. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem. 1997;68(5):2032–2037. PubMed CrossRef
  19. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010; 19(4):353–364. PubMed CrossRef
  20. Stuhec M, Lukić P, Locatelli I. Efficacy, acceptability, and tolerability of lisdexamfetamine, mixed amphetamine salts, methylphenidate, and modafinil in the treatment of attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis. Ann Pharmacother. 2019;53(2):121–133. PubMed CrossRef
  21. Moran LV, Ongur D, Hsu J, et al. Psychosis with methylphenidate or amphetamine in patients with ADHD. New Engl J Med. 2019;380(12):1128–1138. PubMed CrossRef
  22. McElroy SL, Martens BE, Mori N, et al. Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30(1):6–13. PubMed CrossRef
  23. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73–82. PubMed CrossRef
  24. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159–171. PubMed CrossRef
  25. Frye MA, Yatham L, Ketter TA, et al. Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies. Acta Psychiatr Scand. 2009;120(1):10–13. PubMed CrossRef
  26. Muralidharan A, Kotwicki RJ, Cowperthwait C, et al. Parental relationships and behavioral approach system dysregulation in young adults with bipolar disorder. J Clin Psychol. 2015;71(4):387–401. PubMed CrossRef
  27. Adamson SJ, Kay-Lambkin FJ, Baker AL, et al. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug alcohol dependence. 2010;110(1-2):137–143. PubMed CrossRef
  28. Montgomery S, Åsberg M. A new depression scale designed to be sensitive to change. Acad Department Psychiatry Guy’s Hosp. 1977.
  29. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
  30. Posner K, Brent D, Lucas C, et al. Columbia-Suicide Severity Rating Scale (C-SSRS). 10. New York, NY: Columbia University Medical Center; 2008.
  31. Wechsler D. The measurement and appraisal of adult intelligence; 1958.
  32. Krupp LB, LaRocca NG, Muir-Nash J, et al. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Archives neurology. 1989;46(10):1121–1123. PubMed CrossRef
  33. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. sleep. 1991;14(6):540–545. PubMed CrossRef
  34. Kini V, Ho PM. Interventions to improve medication adherence: a review. JAMA. 2018;320(23):2461–2473. PubMed CrossRef
  35. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161(3):564–566. PubMed CrossRef
  36. Zarate CA, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56(1):54–60. PubMed CrossRef
  37. Hasselblad V, Hedges LV. Meta-analysis of screening and diagnostic tests. Psychol Bull. 1995;117(1):167–178. PubMed CrossRef
  38. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd Edition ed.; 1988:567.
  39. McAllister-Williams RH, Goudie N, Azim L, et al. A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study). J Psychopharmacol. 2025;39(2):106–120. PubMed CrossRef
  40. Nunez NA, Singh B, Romo-Nava F, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. Bipolar Disord. 2020;22(2):109–120. PubMed CrossRef
  41. Tsapakis EM, Preti A, Mintzas MD, et al. Adjunctive treatment with psychostimulants and stimulant-like drugs for resistant bipolar depression: a systematic review and meta-analysis. CNS Spectr. 2020:1–12. PubMed CrossRef
  42. Szmulewicz AG, Angriman F, Samamé C, et al. Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis. Acta Psychiatr Scand. 2017;135(6):527–538. PubMed CrossRef
  43. Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry. 2000;48(6):445–457. PubMed CrossRef
  44. Wingo AP, Ghaemi SN. Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients. Psychopharmacol Bull. 2008;41(4):37–47. PubMed
  45. Viktorin A, Rydén E, Thase ME, et al. The risk of treatment-emergent mania with methylphenidate in bipolar disorder. Am J Psychiatr. 2017; 174(4):341–348. PubMed CrossRef
  46. Salazar de Pablo G, Aymerich C, Chart-Pascual JP, et al. Occurrence of psychosis and bipolar disorder in individuals with attention-deficit/hyperactivity disorder treated with stimulants: a systematic review and meta-analysis. JAMA Psychiatry. 2025;82(11):1103–1112. PubMed CrossRef
  47. Moran LV, Skinner JP, Shinn AK, et al. Risk of incident psychosis and mania with prescription amphetamines. Am J Psychiatry. 2024;181(10):901–909. PubMed CrossRef
  48. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatr. 2009;166(9):992–1001. PubMed CrossRef
  49. Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events?: a systematic review. BMC Cardiovasc Disord. 2012;12(1):1–10. PubMed CrossRef
  50. Tadrous M, Shakeri A, Chu C, et al. Assessment of stimulant use and cardiovascular event risks among older adults. JAMA Netw Open. 2021;4(10):e2130795. PubMed CrossRef
  51. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. New Engl J Med. 2011;365(20):1896–1904. PubMed CrossRef
  52. Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374(4):363–371. PubMed CrossRef
  53. Forrest J, Chen W, Jagadheesan K. Misuse and diversion of stimulant medications prescribed for the treatment of ADHD: a systematic review. Front Psychiatry. 2025;16:1612785. PubMed CrossRef
  54. Callovini T, Janiri D, Segatori D, et al. Examining the myth of prescribed stimulant misuse among individuals with attention-deficit/hyperactivity disorder: a systematic review. Pharmaceuticals. 2024;17(8):1076. PubMed CrossRef
  55. Miskowiak KW, Obel ZK, Guglielmo R, et al. Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: a systematic review by the ISBD Targeting Cognition Task Force. Bipolar Disord. 2024;26(3):216–239. PubMed CrossRef
  56. Yalin N, Yildiz A. Improving cognition in bipolar disorder: a systematic review of current pharmacological and nutraceutical approaches. Neuropsychobiology. 2026;85(3):1–24. PubMed CrossRef
  57. Goodwin GM, Anderson I, Arango C, et al. ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacol. 2008;18(7):535–549. PubMed CrossRef
  58. Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018(8).
  59. Huneke NTM, Fusetto VG, Garner M, et al. Expectancy effects, failure of blinding integrity, and placebo response in trials of treatments for psychiatric disorders: a narrative review. JAMA Psychiatry. 2025;82(5):531–538. PubMed CrossRef
Buy PDF for $40

Please sign in or purchase this PDF for $40.